HC Reform Update from Mark Sanna: In yet another setback in efforts to treat Alzheimer’s disease, Eli Lilly & Company announced on Tuesday that it had halted development of an experimental treatment after the compound, called semagacestat, actually made patients worse in two late-stage clinical trials.